Mosunetuzumab with polatuzumab vedotin effective in range of

NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.The overall response rate was 54% in younger patients and 72% in older patients, Adam J. Olszewski, MD, presenting author, said.

Related Keywords

Rhode Island , United States , Mindy Valcarcel , Bycory Perla , Adamj Olszewski , Genentech , Brown Physicians Inc , Brown University Warren Alpert Medical School , Adaptive Biotechnologies Genentech , Blue Cross , Blue Shield , Brown Physicians , Brown University , Warren Alpert Medical School ,